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Objective: To longitudinally assess whether risk adjustment in Associating
Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS)
occurred over time and is associated with postoperative outcome.
Background: ALPPS is a novel 2-stage hepatectomy enabling resection of
extensive hepatic tumors. ALPPS has been criticized for its high mortality,
which is reported beyond accepted standards in liver surgery. Therefore,
adjustments in patient selection and technique have been performed but have
not yet been studied over time in relation to outcome.
Methods: ALPPS centers of the International ALPPS Registry having per-
formed 10 cases over a period of 3 years were assessed for 90-day
mortality and major interstage complications (3b) of the longitudinal study
period from 2009 to 2015. The predicted prestage 1 and 2 mortality risks were
calculated for each patient. In addition, questionnaires were sent to all centers
exploring center-specific risk adjustment strategies.
Results: Among 437 patients from 16 centers, a shift in indications toward
colorectal liver metastases from 53% to 77% and a reverse trend in biliary
tumors from 24% to 9% were observed. Over time, 90-day mortality
decreased from initially 17% to 4% in 2015 (P ¼ 0.002). Similarly, major
interstage complications decreased from 10% to 3% (P ¼ 0.011). The
reduction of 90-day mortality was independently associated with a risk
adjustment in patient selection (P < 0.001; OR: 1.62; 95% CI: 1.36–1.93)
and using less invasive techniques in stage-1 surgery (P ¼ 0.019; OR: 0.39;
95%CI: 0.18–0.86). A survey indicated risk adjustment of patient selection in
all centers and ALPPS technique in the majority (80%) of centers.
Conclusions: Risk adjustment of patient selection and technique in ALPPS
resulted in a continuous drop of early mortality and major postoperative
morbidity, which has meanwhile reached standard outcome measures
accepted for major liver surgery.
Keywords: ALPPS, colorectal liver metastases, less invasive ALPPS
variants, outcome, risk adjustment, two-stage hepatectomy
(Ann Surg 2017;xx:xxx–xxx)
A ssociating Liver Partition and Portal vein Ligation for StagedHepatectomy (ALPPS) is a novel 2-stage hepatectomy variant
that combines portal vein occlusion and parenchymal transection at
the first stage.1,2 The major advantage of this procedure is an
exceptionally fast liver growth compared with ‘‘conventional’’
2-stage hepatectomies3–6 enabling a higher resectability rate.7 The
initial enthusiasm for the procedure has been consistently challenged
due to the high reported morbidity and mortality labeling this
procedure as a high-risk operation.7 Some hepatobiliary centers have
therefore discontinued performing this operation.
Many surgical procedures including liver surgery have expe-
rienced unfavorable outcomes in the beginning, which was followed
by continuous improvement with more careful patient selection and
technical refinement. Previous reports on ALPPS, most of them with
a small number of patients, reveal a wide range of early postoperative
mortality ranging from 1% to 25%.8–13 All of these studies are
mainly reporting morbidity and mortality rates of pooled populations
and outcome studies of ALPPS over time are lacking.
Therefore, the aim of the present study was to analyze whether
adjustments in patient selection, ALPPS technique, and interstage
management occurred and whether those were associated with
change of morbidity and mortality over time. For this purpose, we
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designed a longitudinal cohort study based on identified centers of
the International ALPPS Registry meeting the inclusion criteria.
METHODS
Study Design
The present ALPPS cohort study is composed of data derived
from the International ALPPS Registry. The registry was set up in
2012 and is co-ordinately maintained by the Department of Surgery,
University of Zurich, Switzerland, approved by the Cantonal
Ethics Committee of Zurich (KEK 2013-0326) and is registered at
ClinicalTrials.gov (NCT01924741). The registry serves as a data
platform to prospectively collect the worldwide experience of this
procedure using a web-based data capture system secuTrial (Inter-
active System, Berlin, Germany). Using a longitudinal study design,
the objective of the study was to investigate whether risk adjustment
and technical modifications occurred over time and whether those
changes had an impact on early outcome including morbidity and
mortality. The study was approved by the Scientific Committee of the
ALPPS Registry on May 18, 2016 (http://www.alpps.net/?q=node/
82). Registry data were exported for the current analysis on
August 29, 2016. Questionnaires were sent to all centers exploring
center-specific risk adjustment strategies.
Definition of the Study Population
In an attempt to longitudinally monitor the effect of risk
adjustment over time, only ALPPS centers entering 10 cases over
a duration 3 years were considered for the study population.
Patients of eligible centers who were captured in the International
ALPPS Registry until December 31, 2015 were included in the
analysis. All centers fulfilling the inclusion criteria were approached
(i) to provide missing data commonly observed in registries, (ii) to
provide detailed information on procedure-related technique not
captured in the registry (eg, technical variants14), and (iii) to disclose
their individual strategy of risk adjustment for ALPPS over time
using a survey questionnaire (Table 1).
Risk Adjustment and Outcome Measures
Primary outcome measures were 90-day mortality after stage
1 surgery as well as major interstage and poststage 2 complications
(3b) as a global performance metrics of procedure-related morbid-
ity over time starting from the first registered cases in 2009 until the
end of 2015.
Secondary outcome measures included comorbidities (Charl-
son comorbidity index, cardiovascular disease, chronic obstructive
pulmonary disease, diabetes, and renal disease), size and growth of
the future liver remnant [standardized future liver remnant (sFLR),
future liver remnant/bodyweight, sFLR increase, D sFLR], concom-
itant resections, interstage interval defined as time period between
stage 1 and stage 2 surgery, liver failure using Model of End-stage
Liver Disease score and International Study Group of Liver Surgery
criteria, laboratory tests at poststage-1 day 5 and prestage-2, feasi-
bility of stage 2, and length of intensive care unit and hospital stay.
Risk adjustment was tested by calculating the predicted pre-
stage 1 and 2 mortality risks15 for each patient incorporating age,
tumor entity, interstage complications 3b, and prestage 2 serum
bilirubin and creatinine15 (Supplementary Table 1, http://links.
lww.com/SLA/B310). The analysis was performed for the periods
2011, 2012, 2013, 2014, and 2015. Furthermore, the development
of technical refinements of the ‘‘classical’’ ALPPS procedure14
toward less invasive ALPPS variants (‘‘technically modified
ALPPS’’), including portal vein embolization (PVE)-ALPPS, Partial
ALPPS, Laparoscopic ALPPS, Tourniquet ALPPS, andMini-ALPPS
was longitudinally analyzed (Supplementary Table 2, http://links.
lww.com/SLA/B310). The combination of at least 2 of the latter
variants was summarized as ‘‘combined modification.’’
Statistical Analysis
Descriptive Statistics and Univariate Analysis
Data were expressed using median and interquartile range for
continuous and absolute number (%) for categorical variables.
Longitudinal trends between the years of ALPPS performed were
calculated using Spearman’s r correlation for continuous variables
and Kendalls t for categorical variables. In preparation for multivar-
iate analysis on 90-day mortality and major interstage complications,
variables of interest were tested using Kruskal–Wallis test for
continuous and x2 square test for categorical variables. Only clini-
cally useful parameters selected in a discussion between biostatis-
tician and clinician were included in regression analysis avoiding
automatic variable selection. P values  0.05 were considered
statistically significant.
Multivariate Logistic Regression Analysis
Variables, which showed a statistically significant change over
time, were considered for regression analysis. Parameters, which
were hypothesized to reduce 90-day mortality and major interstage
complications were subsequently split into 2 categories: (1) variables
representing risk adjustment (prestage-1 and prestage-2 risk) and (2)
variables representing the technical refinement of the procedure. The
influence of the respective variables was quantified using odds ratio
(OR) and 95% confidence interval (CI). Calibration of regression
models was assessed using the Hosmer–Lemeshow test.
All statistical analyses were performed using IBM SPSS
Statistics version 22 forMacintosh (IBMCorporation, Armonk, NY).
RESULTS
Study Population With Improved Data Quality
Of 836 registered patients from 123 centers, 16 centers (13%)
were identified meeting the inclusion criteria (at least 10 cases over a
period of 3 yr), providing a total of 437 patients for analysis.
Percent of data completeness of registry-captured variables has been
significantly increased from 86% (75%–94%) at the time of registry
data export to 97% (92%–99%) after approaching all centers. In
addition, new information on technical aspects of ALPPS variants,
which did not exist in the registry, was collected reaching 99% of
data completeness.
Participating centers were mainly located in Europe (n ¼ 11),
followed by Asia (n¼ 2), South America (n¼ 2), and North America
TABLE 1. Survey With Response of 16/16 (100%)
Survey Questions n %
Was patient selection adjusted? (yes/no) 16/16 100/0
Patient selection was adjusted for:
Age 10 63
Tumor entity 14 88
Risk assessment before surgery 8 50
Liver function testing 10 63
Timing of stage 2 11 69
Was ALPPS technique modified over time? (yes/no) 12/4 75/25
Did risk adjustment or technique improve
safety of ALPPS? (yes/no)
16/16 100/0
Refers to following parameters: ALPPS risk score (n ¼ 1), ASA (n ¼ 2), ECOG
(n ¼ 1), frailty (n ¼ 1), BMI (n ¼ 1), cardiopulmonary reserve (n ¼ 3).
ASA indicates American Society of Anesthesiologists Score; BMI, body mass
index; ECOG, Eastern Cooperative Oncology Group Score.
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(n ¼ 1). A median number of 26 (17–35) patients per center were
enrolled over a median period of 5 years (4–5 yr). Eleven of
16 (69%) centers started ALPPS in the early period (2011) and
5 centers (31%) in 2012. ALPPS procedures were annually distrib-
uted with 48 (11%), 103 (24%), 101 (23%), 105 (24%), and 79 (18%)
for the annual periods 2011, 2012, 2013, 2014, and 2015 (Supple-
mentary Table 3, http://links.lww.com/SLA/B310).
Survey Exploring Center-specific Risk Adjustment
Strategies
Before analysis, all centers participated in a survey exploring
center-specific risk adjustment strategies (Table 1). All centers
(n ¼ 16) stated that they adjusted patient selection over time for
age (63%), risk assessment before surgery (50%), liver function
testing (63%), and timing of stage-2 surgery (69%). The majority of
centers (75%) modified their surgical ALPPS technique.
Longitudinal Improvement of Procedure-related
Safety
Study population characteristics are presented in Table 2, and
operative characteristics in Table 3. Over time, there was a significant
decrease in the annual 90-day mortality rate (t¼0.124; P¼ 0.002)
starting from 17% in the early period (2011) to 3.8% in 2015
(Fig. 1A). This development was parallelly accompanied by a steady
reduction of the annual overall (t ¼ 0.151; P < 0.001) and major
(t¼ 0.102; P ¼ 0.011) interstage complication rates with 78% and
10% for the period 2011 versus 56% and 3% for 2015 (Fig. 1B,
Table 4).
In the same line, the prestage-2 ALPPS risk model as a
measure of interstage performance revealed a substantial decrease
over time from a mean of 11.6% to 3.1% (r¼ 0.260; P < 0.001;
Fig. 1A). Interstage serum bilirubin and international normalized
ratio levels, Model of End-stage Liver Disease, as well as intensive
care unit stay significantly decreased over time (Table 4).
Liver volumetric measures before stage-2 such as sFLR and
future liver remnant/bodyweight ratio changed toward smaller vol-
umes over time (Table 4). Liver mass gain, as measured by D sFLR,
also slightly decreased over time (Table 4). Interestingly, a prolonga-
tion of the interstage interval (10 d in the early period 2011 vs
14 d in 2015) was noted (Table 4). This development and the
increasingly use of functional liver tests indicate a more cautious
progression to stage-2 surgery. Failure to reach stage-2 surgery
slightly increased over time with a borderline significance (r ¼
0.051; P ¼ 0.467; Table 4). Of note, causes of mortality did not
change significantly over the years. For the periods 2011, 2012,
2013, 2014, and 2015 liver failure occurred in 3, 5, 7, 3, and 2 cases
(t ¼ 0.084, P ¼ 0.507), death of sepsis/infection in 8, 7, 6, 5, and
1 cases (t ¼ 0.219, P ¼ 0.070), cardiac death in 0, 2, 1, 0, and 0
cases (t¼0.064, P¼ 0.420), and other causes of death in 0, 5, 2, 2,
and 0 cases (t¼ 0.007, P¼ 0.951). Due to the fact, that death of liver
failure or sepsis/infection is in some cases difficult to distinguish, in
8 patients cause of death was categorized for both.
TABLE 2. Study Population
Completeness
(%)
Parameter Before After 2011 2012 2013 2014 2015 Correlation P
Demographics
Age, yr 96 100 63 (54–71) 62 (53–70) 63 (56–70) 62 (52–71) 59 (49–65) 0.107 0.026
Sex; male, n, % 98 100 29 (60) 59 (57) 72 (71) 62 (59) 49 (62) 0.011 0.809
BMI, kg/m
2
97 100 25 (23–28) 26 (23–28) 27 (24–29) 25 (23–29) 25 (23–29) 0.017 0.726
Tumor
CRLM, n, % 94 99 27 (53) 62 (59) 75 (75) 76 (73) 61 (77) 0.127 0.003
Biliary tumor, n, % 94 100 12 (24) 21 (20) 14 (14) 17 (16) 7 (9) 0.107 0.013
HCC, n, % 90 99 1 (2) 10 (9) 7 (7) 5 (5) 3 (4) 0.040 0.311
Other, n, % 94 99 11 (21) 13 (12) 4 (4) 6 (6) 8 (10) 0.104 0.039
Comorbidities
Charlson comorbidity index — 100 6 (2–6) 6 (3–8) 6 (4–7) 6 (4–7) 6 (4–6) 0.021 0.665
Cardiovascular disease, n, % 98 100 17 (35) 42 (41) 44 (44) 32 (31) 20 (25) 0.093 0.026
COPD, n, % 98 100 2 (4) 1 (1) 3 (3) 4 (4) 2 (3) 0.015 0.728
Diabetes, n, % 98 100 4 (8) 11 (11) 8 (8) 13 (13) 4 (5) 0.022 0.594
Renal disease, n, % 98 100 3 (6) 2 (2) 1 (1) 1 (1) 0 (0) 0.100 0.048
Liver baseline characteristics
sFLR 88 95 0.23 (0.16–0.29) 0.24 (0.17–0.30) 0.22 (0.17–0.26) 0.23 (0.19–0.28) 0.21 (0.16–0.26) 0.033 0.502
FLR/BW 88 96 0.37 (0.27–0.52) 0.37 (0.28–0.49) 0.37 (0.29–0.48) 0.36 (0.29–0.45) 0.31 (0.25–0.48) 0.081 0.097
Bilobar tumor, n, % — 98 25 (52) 67 (65) 63 (64) 71 (71) 55 (71) 0.095 0.030
Chemotherapy

, n, % 98 100 20 (74) 56 (90) 69 (92) 69 (91) 58 (95) 0.112 0.043
Steatohepatitis, n, % 48 74 7 (22) 7 (10) 9 (12) 11 (14) 8 (12) 0.024 0.645
Fibrosis, n, % 46 76 7 (21) 12 (16) 14 (19) 18 (22) 10 (14) 0.015 0.759
Macrosteatosis, n, % 45 75 6 (18) 23 (31) 20 (28) 22 (28) 17 (25) 0.003 0.959
Serum Creatinine, mg/dL 82 92 0.84 (0.60– 0.98) 0.78 (0.65–0.90) 0.84 (0.70–0.92) 0.81 (0.70–0.90) 0.81 (0.62–0.95) 0.000 0.996
Serum Bilirubin, mg/dL 91 98 0.60 (0.40–0.98) 0.64 (0.41–0.90) 0.50 (0.40–0.78) 0.50 (0.36–0.70) 0.50 (0.32–0.70) 0.219 <0.001
INR 86 91 1.0 (0.9–1.1) 1.0 (0.9–1.1) 1.0 (0.9–1.1) 1.0 (0.9–1.1) 1.0 (0.9–1.1) 0.018 0.719
MELD 76 84 7 (6–8) 6 (6–8) 7 (6–8) 6 (6–7) 6 (6–7) 0.066 0.203
Continuous variables presented as median and interquartile range (IQR), correlation with Spearmans r; categorical variables presented as count and percent (%), correlation with
Kendalls t.
Refers to CRLM only.
BMI indicates body mass index; COPD, chronic obstructive pulmonary disease; FLR/BW, future liver remnant/bodyweight; INR, international normalized ratio; MELD, Model of
End-stage Liver Disease.
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Adjustment in Patient Selection Is Associated With
Reduced Early Mortality
The prestage-1 risk model of the ALPPS Risk Score15 was
used as a standardized measure of patient selection for ALPPS
upfront. A significant shift toward younger patients (63 yr in
2011 to 59 yr in 2015) as well as toward colorectal liver metastases
(CRLM) (53% in 2011 to 77% in 2015) with concomitant decline
in biliary tumors (24% in 2011 to 9% in 2015) was observed
(Fig. 1C, Table 2). These changes in age and indications are also
reflected in a significant annually drop of the mean predicted pre-
stage-1 mortality risks (24% in 2011 vs 9% in 2015; r ¼ 0.168;
P < 0.001) (Fig. 1A).
Of note, CRLM patients in the later periods were more likely
to undergo chemotherapy than in the earlier periods suggesting a
more cautious management in terms of response to chemotherapy
(Table 2).
Multivariate logistic regression analysis identified the pre-
stage 1 risk model to be independently associated with a decline in
90-day mortality (P < 0.001; OR: 1.62; 95% CI: 1.36–1.93; Sup-
plementary Table 4, http://links.lww.com/SLA/B310). The Hosmer–
Lemeshow test revealed a stable model fit (P ¼ 0.429).
Less Invasive ALPPS Techniques Are Associated
With Improved Safety
Technically modified ALPPS procedures were independently
developed to reduce invasiveness of stage 1 surgery aiming to
improve safety. Over time, there was significantly increased use
of less invasive ALPPS variants (t ¼ 0.098; P ¼ 0.027), including
PVE-ALPPS, Partial ALPPS, Laparoscopic ALPPS, Tourniquet
ALPPS, and Mini-ALPPS with a corresponding decline of ‘‘classic’’
ALPPS cases (t ¼ 0.102; P ¼ 0.021) (Fig. 1D, Table 3). In 2015,
less invasive variants represented the half of all ALPPS cases (52%)
of which partial ALPPS was the most frequently performed variant
(68%).
Independently of patient selection using the prestage 1 risk
model, multivariate regression analysis showed that less invasive
ALPPS variants were associated with decreased 90-day mortality
rates (P ¼ 0.019; OR: 0.39; 95% CI: 0.18–0.86; Supplementary
Table 4, http://links.lww.com/SLA/B310). When the variable ‘‘year
of ALPPS performed’’ was included into the regression model, the
analysis revealed that the year of ALPPS performed did not signifi-
cantly affect the outcome (P¼ 0.085; Supplementary Table 4, http://
links.lww.com/SLA/B310). This implies that improved outcome of
less invasive variants is not exclusively a result of a potential learning
curve bias of early cases.
Adjustment in Patient Selection and ALPPS
Technique Results in Improved Interstage
Complication Profile
To further investigate why patient selection and technical
refinement of stage 1 surgery translates into a dramatic decrease
of early mortality, we tested whether this finding was accompanied
by a parallel reduction of major interstage complications. Both
overall (t ¼ 0.151; P < 0.001) and major (t ¼ 0.102; P ¼
0.011) interstage complications significantly declined over time
(Fig. 1B). Multivariate regression analysis demonstrated that a
TABLE 3. Operative Characteristics
Completeness
(%)
Parameter Before After 2011 2012 2013 2014 2015 Correlation P
‘‘Classic’’ ALPPS

, n, % — 100 33 (69) 69 (66) 75 (74) 71 (68) 38 (48) 0.102 0.021
Technically modified ALPPS, n, % — 100 15 (31) 35 (34) 26 (26) 34 (32) 41 (52) 0.098 0.027
One modification, n, % — 100 14 (29) 31 (30) 18 (18) 29 (28) 24 (30) 0.004 0.928
Combined modification
y
(>1), n, % — 100 1 (2) 4 (4) 8 (8) 5 (5) 17 (22) 0.173 <0.001
PVE-ALPPS, n, % — 99 6 (13) 4 (4) 11 (11) 7 (7) 8 (10) 0.015 0.741
Partial ALPPS, n, % — 99 5 (10) 10 (10) 13 (13) 20 (20) 28 (36) 0.180 <0.001
Tourniquet ALPPS, n, % — 99 5 (10) 19 (18) 9 (9) 8 (8) 5 (6) 0.096 0.024
Laparoscopic ALPPS stage 1, n, % 77 99 1 (2) 3 (3) 1 (1) 0 (0) 6 (8) 0.055 0.319
Laparoscopic ALPPS stage 2, n, % — 100 1 (2) 3 (3) 1 (1) 2 (2) 6 (8) 0.068 0.188
Mini-ALPPS, n, % — 99 0 (0) 0 (0) 0 (0) 2 (2) 8 (10) 0.180 0.001
Rescue ALPPS, n, % — 99 6 (13) 4 (4) 9 (9) 11 (11) 2 (3) 0.029 0.480
Stage 1
Concomitant resections, n, % — 99 7 (15) 14 (14) 8 (8) 8 (8) 5 (6) 0.087 0.048
Colorectal resections, n, % — 99 2 (4) 5 (5) 11 (11) 7 (7) 4 (5) 0.013 0.742
Gastric/bowel resections, n, % — 99 3 (6) 1 (1) 2 (2) 1 (1) 1 (1) 0.058 0.250
Pancreatic resections, n, % — 99 1 (2) 4 (4) 0 (0) 1 (1) 0 (0) 0.083 0.066
Cleaning of the FLR, n, % 40 99 19 (40) 58 (55) 53 (53) 57 (55) 52 (67) 0.101 0.018
Operation time, min 81 99 331 (268–480) 330 (240–330) 317 (241–420) 300 (216–405) 320 (225–433) 0.060 0.211
Pringle, n, % 53 95 15 (34) 22 (22) 31 (32) 23 (23) 21 (30) 0.005 0.919
Transfusion, n, % 95 100 12 (25) 21 (20) 20 (20) 18 (17) 6 (8) 0.111 0.007
Stage 2
Concomitant resections, n, % — 100 1 (2) 2 (2) 2 (2) 2 (2) 3 (4) 0.030 0.527
Colorectal resections, n, % — 100 1 (2) 1 (1) 0 (0) 2 (2) 2 (3) 0.033 0.525
Gastric/bowel resections, n, % — 98 0 (0) 0 (0) 0 (0) 1 (1) 0 (0) 0.032 0.318
Pancreatic resections, n, % — 98 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0.005 0.399
Operation time, min 66 95 156 (120 – 213) 150 (120–200) 155 (110 – 218) 153 (115 – 213) 175 (116 – 259) 0.038 0.444
Continuous variables presented as median and interquartile range (IQR), correlation with Spearmans r; categorical variables presented as count and percent (%), correlation with
Kendalls t.
Refers to the initially described procedure (REF 1,2).
yCombination of at least 2 of the following 5 ALPPS variants.
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reduction of prestage 1 risk, which reflects patient selection,
is associated with a decrease in major interstage complications
(P ¼ 0.011; OR 1.26, 95% CI 1.06–1.51; Supplementary Table 4,
http://links.lww.com/SLA/B310). Furthermore, less invasive ALPPS
variants were associated with a reduction of major interstage com-
plications (P ¼ 0.035; OR 0.40; 95% CI 0.17–0.94; Supplementary
Table 4, http://links.lww.com/SLA/B310), underlining the impact of
less invasive techniques on favorable interstage course.
DISCUSSION
This longitudinal cohort study demonstrated for the first time
that risk adjustment in patient selection, and technical modifications
toward less invasive ALPPS procedures, and interstage management
occurred over time. These changes resulted in a continuous drop of
early mortality and major postoperative morbidity, which has mean-
while reached standard outcome accepted for major liver surgery.
ALPPS has initiated hot debates on its safety and efficacy
among experienced hepatobiliary surgeons with opposite attitudes of
advocating or refusing this procedure.7 One major drawback of this
procedure is the high early mortality rate, which was reported in
initial series between 10% and 20%.9,11–13,16 Even a recent ALPPS
registry analysis looking at centers with5 registered patients found
an overall 90-day mortality rate of 9%.15 Today, these data need to be
put in perspective since 5 years have passed since the inaugural
description of ALPPS1,2 and 8 years since the first recorded cases in
the ALPPS registry. However, previous ALPPS studies analyzed only
pooled data of entire time periods10,15,17 but longitudinal observation
studies, which are focused on change in patient characteristics and
outcome over time, are generally rare in surgical mortality studies18
and have not yet been reported in ALPPS. To monitor changes or
adjustments over time, a longitudinal study design requires a mini-
mum length of observation period as well a minimum number of
ALPPS cases performed within this period. To consider these
requirements, we included only centers, which reported at least
10 cases over a minimum period of 3 years.
The central observation of the study is the dramatic decrease in
early mortality after ALPPS. The unacceptable 90-day mortality rate
of 17% in the early pioneer period steadily improved to 4% in 2015.
This favorable development represents a major milestone for ALPPS
that now compares with the standard outcome accepted for major
liver surgery7,19 To study which factors are the main contributors for
this development, we dissected the analysis into 3 categories looking
at adjustment of patient selection, technical modification, and
interstage management.
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FIGURE 1. Decline of ALPPS associated 90-day mortality (A). Mortality rates significantly improved from 16.7%, 16.5%, 12.9%,
9.5%, to 3.8% in the respective years2011, 2012, 2013, 2014, and 2015 (P¼ 0.009). Reduction of early mortality over time was
associated with a gradual decline of themean predicted prestage 1 and prestage 2mortality risks indicating risk reduction. Prestage
1 and prestage 2 mortality risks were calculated for each patient according to the previously published ALPPS risk formuala15 using
the variables age, tumor entity, interstage complications 3b, and prestage 2 serum bilirubin and creatinine. Mean predicted risks
dropped in the prestage 1 model from 12.4%, 11.0%, 10.3%, 10.3%, to 6.0% (P < 0.001) and in the prestage 2 model from
11.6%, 13.2%, 11.0%, 8.6% to 3.1% (P < 0.001) in the annual periods 2011, 2012, 2013, 2014, and 2015. Total and major
interstage complications dropped from 78% to 56% (P ¼ 0.001), and 10% to 3% (P ¼ 0.020) in the periods 2011 and 2015 (B).
Indications for ALPPS significantly changed over timewith an increase in CRLM and a decline in biliary tumors (C). (D) This illustrates
the technical development of ALPPS over time. PVE-ALPPS, Partial ALPPS, Laparoscopic ALPPS, Tourniquet ALPPS, and Mini-ALPPS
were categorized as ‘‘modified ALPPS’’ as opposed to ‘‘classic’’ ALPPS as initially described.1,2 In 2015, 52%weremodified ALPPS as
compared with 31% in 2011. Partial ALPPS was the most common technical modification, representing 68% of all technically
modified ALPPS.
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Patient selection is one of the key principles for improving
outcome in surgery.20 In the present study, a significant age shift to
younger patients as well as a shift toward more colorectal liver
metastases and less biliary tumors were characteristic changes over
time. The decline of the mean predicted prestage 1 risk of early
mortality,15 which incorporates both variables age and tumor type,
illustrates that the risk was lowered by adjusting age and tumor
indication over time. These observations go along with the results of
the survey where the majority of centers stated that risk adjustment in
patient selection was performed for age and tumor indication
(Table 1). Independently of the present study, age has been reported
as crucial factor for mortality in ALPPS15,17 and many centers have
also observed favorable outcomes for CRLM8,17,21 but inferior
results for biliary tumors.9,17,22 Another important observation of
this study was the decreasing proportion of ALPPS patients with
cardiovascular disease. Although prevalent cardiovascular disease
was not an element of the prestage 1 risk prediction model,15 the
negative impact of this comorbidity on postoperative outcome has
been well documented in major liver surgery23 and might be also a
contributing factor of risk adjustment in the present study.
Several technical modifications of the ALPPS operation have
been developed which include the variants14,24 PVE-ALPPS,25 Par-
tial ALPPS,26,27 Laparoscopic ALPPS,28 Tourniquet ALPPS,29 and
Mini-ALPPS.30 All variants have in common less invasive stage 1
surgery aiming to avoid major interstage complications and to
improve safety of the procedure. Despite the less invasiveness, rapid
hypertrophy is not considerably impaired in ALPPS variants com-
pared with the classical procedure.8,27,30 In the present study, we
observed a trend of increasingly performed ALPPS variants and a
concurrent decrease of classical procedures (Fig. 1D). In accordance
with this observations, the majority of centers stated in the survey
that ALPPS technique has been modified over time (Table 3).
Although comparing studies suggest superior outcome for less
invasive techniques,8,27,30 none of them could statistically demon-
strate that less invasiveness is associated with reduced early morta-
lity, mainly due to the small sample and event size. We therefore
tested in the present cohort whether less invasive ALPPS is indepen-
dently associated with 90-day mortality and demonstrated for the
first time that less invasiveness is an independent risk factor for
reduced mortality (Supplementary Table 4, http://links.lww.com/
SLA/B310). Since regression analysis was controlled for the year
of ALPPS performed, the novel finding of reduced mortality appears
not to be superimposed by a potential learning curve bias and is rather
a inherent characteristic of the less invasive procedure itself. The
observed lower interstage complication rate in less invasive techni-
ques might be also an additional contributing factor for lower
mortality observed in modified ALPPS (Supplementary Table 4,
http://links.lww.com/SLA/B310).
Following stage 1 surgery, greatest attention needs to be
directed to the interstage course. In our study, interstage management
was evaluated by the length of the interstage interval as well as liver
function tests and occurrence of complications during the interstage
course. The importance of an uneventful interstage course in terms of
normal renal and hepatic function as well as avoidance of compli-
cations has been repeatedly reported.13,15,17 As demonstrated in our
study, interstage complications are mainly influenced by patient
selection and ALPPS technique while interstage renal and hepatic
function might be modified by extending the interstage interval until
both organ functions reach normal range.15,17 The observed pro-
longation of the interstage interval was accompanied by increasingly
used liver function testing in our study. This implies the importance
of liver function tests for guiding safe progression with stage 2
TABLE 4. Interstage and Poststage 2 Course
Completeness
(%)
Parameter Before After 2011 2012 2013 2014 2015 Correlation P
Interstage course
sFLR 87 95 0.36 (0.30–0.45) 0.41 (0.33–0.49) 0.36 (0.30–0.45) 0.37 (0.30–0.44) 0.35 (0.29–0.42) 0.116 0.019
sFLR increase, % 80 91 84 (43–113) 74 (50–107) 77 (43–101) 61 (39–93) 82 (45–117) 0.053 0.288
D sFLR 81 92 0.28 (0.17–0.40) 0.27 (0.20–0.42) 0.27 (0.17–0.34) 0.21 (0.15–0.30) 0.26 (0.17–0.31) 0.128 0.010
FLR/BW 77 95 0.65 (0.48–0.86) 0.69 (0.53–0.85) 0.66 (0.54–0.75) 0.57 (0.48–0.73) 0.58 (0.46–0.72) 0.154 0.002
Interstage interval, d 80 94 10 (7–14) 11 (8–17) 12 (9–17) 11 (8–15) 14 (10–21) 0.128 0.009
Lab tests day 5
Serum bilirubin, mg/dL 91 99 0.80 (0.50–1.45) 0.82 (0.53–1.75) 0.76 (0.60–0.86) 0.67 (0.47–1.21) 0.60 (0.40–0.90) 0.151 0.002
Serum creatinine, mg/dL 77 92 0.70 (0.57–0.90) 0.69 (0.60–0.97) 0.71 (0.60–0.85) 0.67 (0.50–0.80) 0.70 (0.58–0.80) 0.083 0.097
INR 88 93 1.1 (1.0–1.2) 1.2 (1.0–1.3) 1.1 (1.0–1.3) 1.1 (1.0–1.3) 1.1 (1.0–1.2) 0.042 0.395
MELD 72 86 9 (7–11) 9 (7–12) 8 (7–10) 8 (7–11) 8 (6–10) 0.083 0.108
ISGLS 88 97 2 (4) 14 (14) 12 (12) 17 (17) 6 (8) 0.020 0.612
Lab tests prestage 2
Serum bilirubin, mg/dL 91 97 0.70 (0.40–1.10) 0.80 (0.50–1.20) 0.73 (0.40–1.14) 0.60 (0.40–0.90) 0.50 (0.30–0.70) 0.221 <0.001
Serum creatinine, mg/dL 82 91 0.70 (0.60 -0.80) 0.72 (0.58–0.89) 0.76 (0.60–0.86) 0.66 (0.58–0.80) 0.70 (0.60–0.84) 0.044 0.386
INR 86 91 1.1 (1.0–1.2) 1.1 (1.0–1.3) 1.2 (1.0–1.3) 1.1 (1.0–1.2) 1.1 (1.0–1.2) 0.091 0.069
MELD 75 84 8 (6–9) 8 (7–11) 8 (7–11) 8 (6–9) 7 (7–9) 0.128 0.014
Liver function testing

, n, % — 99 11 (21) 25 (24) 20 (20) 31 (30) 30 (39) 0.103 0.021
Interstage complications, n, % 84 97 36 (78) 77 (76) 64 (65) 62 (61) 43 (56) 0.151 <0.001
Interstage complications 3b, n, % 99 100 5 (10) 15 (15) 9 (9) 9 (9) 2 (3) 0.102 0.011
ICU stay, d 71 99 1 (1–3) 2 (1–5) 1 (1–3) 1 (1–3) 1 (1–2) 0.166 0.001
Stage 2 not performed, n, % 98 100 1 (2) 3 (3) 0 (0) 2 (2) 4 (5) 0.051 0.467
Poststage 2 course
Complications stage 2, n, % 71 97 37 (77) 66 (66) 74 (73) 67 (67) 46 (61) 0.062 0.158
Complications stage 2 3b, n, % 71 97 15 (31) 30 (30) 21 (21) 29 (29) 19 (25) 0.027 0.538
ICU stay, d 69 75 2 (0–4) 2 (1–4) 1 (0–4) 1 (0–4) 1 (0–2) 0.142 0.010
Hospital stay, d 73 83 11 (7–34) 10 (7–21) 12 (7–24) 12 (7–22) 12 (8–19) 0.006 0.910
Continuous variables presented as median and interquartile range (IQR), correlation with Spearmans r; categorical variables presented as count and percent (%), correlation with
Kendalls t.
Refers to hepatobiliary scintigraphy, indocyanine green, or LiMAx testing.
ICU indicates intensive care unit; INR, international normalized ratio; ISGLS, International Study Group of Liver Surgery criteria; MELD, Model for End-stage Liver Disease.
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surgery.31,32 Furthermore, the adjustments of interstage management
is also partially mirrored by the decreasing prestage 2 mortality risk
over time since 3 of 4 variables of the prestage 2 risk model are
interstage measures such as interstage major complications, prestage
2 serum bilirubin and creatinine.15
The strength of this study is the transformation of a registry-
based cohort into an international prospectively collected, ALPPS
cohort with a longitudinal study design. This process led to a
significant improvement in data quality and completeness
(Tables 2–4). Further strength of this study is related to gathering
of new data on ALPPS technique, which were not captured by the
registry. This allowed including technical modifications in the
analysis. In addition, an independently undertaken survey on risk
adjustment accompanied the statistical findings of the longitudinal
study. However, this study has also shortcomings, which are associ-
ated with voluntary data entry potentially leading to reporting bias.
To minimize this problem, centers were individually approached to
provide their entire ALPPS experience and avoid missing data.
In conclusion, this longitudinal study demonstrates that risk
adjustment of patient selection, ALPPS technique, and interstage
management resulted in improved outcome of ALPPS over time,
which now compares with standard outcome accepted for major liver
surgery. Despite these remarkable results, there is still room for
continuous improvement in ALPPS for procedure-related safety and
oncological outcome.
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DISCUSSANTS
Pa˚l-Dag Line (Oslo, Norway):
Thank you for the privilege and opportunity to evaluate this
important paper about improvements in patient selection and man-
agement in ALPPS and the impact on early morbidity and mortality.
First, one of the weaknesses of longitudinal studies is that it may be
difficult to detect causal relationships. You have evaluated changes
over time by correlation analysis. Subtle changes over time do not
always imply an underlying relationship. Did you ever consider an
alternative design with treatment period/year as a grouping variable,
and if so, would this alter the statistical approach? Second, it is
difficult to me to assess the significance of less invasive ALPPS
separately from the learning curve and clinical experience gained
throughout the study period. Therefore, from the authors perspective,
what is the most important factor to improve outcomes in ALPPS;
patient selection, interstage management or ALPPS technique (clas-
sical vs technically modified)?
Third, liver failure and sepsis remain the most important
causes of death following ALPPS. Do the authors have any infor-
mation regarding liver function testing in the fatal group in particu-
lar and whether interstage interval length was different from the
other patients? Fourth, regarding the operative characteristics and
ALPPS variants as given in Table 3:Why is rescue ALPPS listed as a
separate category together with classical and technical modified
ALPPS?
Response from Henrik Petrowsky (Zurich,
Switzerland):
Thank you Prof. Line for reviewing our manuscript and I
really appreciate your interesting and important questions that I
would like to answer point by point. Your first question arises the
concern that the observational findings of our study do not necessar-
ily detect causal relationships. Therefore, an important part of our
study was to conduct a multivariant analysis, in which various risk
factors that influence outcome of ALPPS were controlled. We also
included the variable treatment period. Statistical observations over
time is one important element but the multivariant analysis identified
less invasiveness, as well as patient selection using the prestage 1 risk
score as independent predictors regardless in which year ALPPS was
performed. I think we could clearly demonstrate that both risk factors
are independent predictors independently of the year that also
explains risk adjustment.
In your second question, you mentioned that it is difficult to
assess the significance of less invasive ALPPS separately from the
learning curve. This is an important question and I would like to refer
to my previous reply and our multivariant regression analysis. I agree
with you that a certain effect of the learning curve on outcome cannot
be excluded but as mentioned before we controlled our regression
analysis for the year of ALPPS was performed. Despite this
approach, less invasive ALPPS technique was an independent pre-
dictor of improved outcome regardless of the year when ALPPS was
performed. Another independent predictor was prestage 1 risk, which
reflects patient selection. We put all the important and significant
variables of the uni-variant analysis into the multi-variant analysis
including interstage variables, but they did not come out as signifi-
cant. It might be that patient selection influences a favorable inter-
stage outcome. I think that patient selection as well as the use of less
invasive stage 1 surgery is probably the most important factor, which
resulted in improved outcome.
Next, you asked whether liver function testing and interstage
interval were different for the fatal and nonfatal group. Yes, indeed
we looked at these variables and, interestingly, there was no signifi-
cant difference between both groups. In your next question you asked
why rescue ALPPS has been listed as a separate category. The simple
purpose to do so was to provide the reader with figures in which
ALPPS was performed for portal vein embolization failure. I think,
this is an important information to be included in the manuscript.
Christiane Bruns (Cologne, Germany):
Thank you very much for this presentation. I have 2 questions:
You nicely demonstrated that modifications of the ALPPS procedure,
in particular less invasive ALPPS procedures, led to a reduction of
mortality. I am curious to know, how much future liver remnant you
gain with less invasive ALPPS procedures? Is this less invasive
ALPPS procedure really necessary or could the anticipated liver
resection also be performed without the less invasive ALPPS pro-
cedure? You definitely decrease morbidity with less invasive ALPPS
procedures, have you also looked at the oncological outcome of those
patients receiving the less invasive ALPPS compared to patients who
received more invasive ALPPS procedures for instance the recur-
rence free survival in patients with colorectal liver metastases?
Furthermore, have you compared the morbidity and mortality of
patients after the mini-ALPPS and reduced ALPPS procedures to
patients receiving 2-stage hepatectomy if this is possible?
Response from Henrik Petrowsky (Zurich,
Switzerland):
Thank you, Prof. Bruns for your important questions. We
looked into these things and we found that the group of modified
procedures had no major disadvantage in terms of hypertrophy. Even
by partial transection, you achieve almost what you gain with
complete transection. Hypertrophy is not the only critical part of
ALPPS. How much the future liver remnant is instrumented another
important factor for the indication of ALPPS. Interstage complica-
tions might delay stage 2 surgery and start of chemotherapy. There-
fore, it is important that you improve the interstage course so that
these patients don’t get any complications and can proceed to stage 2
surgery. To address your question of oncological outcome and
comparison to 2-stage hepatectomy, we did not look into these topics.
Antonio Pinna (Bologna, Italy):
Nice presentation. Quick questions. First, how do you explain
a better outcome, due to the fact that the functional volume liver
remnant is actually less overtime in the study. I would like to know
how do you explain if the volume is not increasing as much as in the
original group, and how can we have a better outcome?
And my second question is, would it be nice to compare
morbidity and mortality outcome between classical ALPPS and all
the group of modified ALPPS to have a better clue, if this is the right
technique for extended liver disease or rather this technique is just
comparable to a single stage large hepatectomy?
Response from Henrik Petrowsky (Zurich,
Switzerland):
Thank you Prof. Pinna for your relevant questions. Let me first
address your questions on volume increase and outcome. Volume
increase is necessary, but probably not the most critical factor for the
risk of mortality as we also have demonstrated in our previous ESA
paper on the ALPPS risk score where the degree of hypertrophy was
not a significant predictor of early mortality. As I outlined in my
previous comments to Prof. Line, appropriate patient selection and
lowering interstage complications by using less invasive techniques
are probably the 2 most important key elements for improved
outcome. I agree with you, it would be terrific study looking into
all less invasive groups in comparison with the classical procedure.
We tried to look into whether we can split up the different less
invasive groups but the numbers were too small.
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